DE102006053635B4 - Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung - Google Patents

Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Download PDF

Info

Publication number
DE102006053635B4
DE102006053635B4 DE102006053635A DE102006053635A DE102006053635B4 DE 102006053635 B4 DE102006053635 B4 DE 102006053635B4 DE 102006053635 A DE102006053635 A DE 102006053635A DE 102006053635 A DE102006053635 A DE 102006053635A DE 102006053635 B4 DE102006053635 B4 DE 102006053635B4
Authority
DE
Germany
Prior art keywords
formula
compound
combination
compounds
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102006053635A
Other languages
German (de)
English (en)
Other versions
DE102006053635A1 (de
Inventor
Wendelin Dr. 65510 Frick
Heiner Dr. 65719 Glombik
Stefan Dr. 60594 Theis
Hubert Dr. 55270 Heuer
Hans-Ludwig Dr. 65239 Schaefer
Werner Prof. Dr. Dr. 55130 Kramer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102006053635A priority Critical patent/DE102006053635B4/de
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to PL07819434T priority patent/PL2084172T3/pl
Priority to NZ576762A priority patent/NZ576762A/en
Priority to DK07819434.7T priority patent/DK2084172T3/da
Priority to CA2865332A priority patent/CA2865332C/en
Priority to RU2009122470/04A priority patent/RU2456282C2/ru
Priority to MX2009003958A priority patent/MX2009003958A/es
Priority to JP2009536625A priority patent/JP5301453B2/ja
Priority to ES07819434T priority patent/ES2358371T3/es
Priority to HK10102412.4A priority patent/HK1137762B/xx
Priority to AU2007321496A priority patent/AU2007321496B2/en
Priority to KR1020097009914A priority patent/KR101489168B1/ko
Priority to AT07819434T priority patent/ATE492554T1/de
Priority to HR20110197T priority patent/HRP20110197T1/hr
Priority to DE502007006055T priority patent/DE502007006055D1/de
Priority to PCT/EP2007/009393 priority patent/WO2008058628A1/de
Priority to EP07819434A priority patent/EP2084172B1/de
Priority to CA2669230A priority patent/CA2669230C/en
Priority to BRPI0718813A priority patent/BRPI0718813B8/pt
Priority to PT07819434T priority patent/PT2084172E/pt
Priority to SI200730487T priority patent/SI2084172T1/sl
Priority to MYPI20091688A priority patent/MY148429A/en
Priority to NO20091893A priority patent/NO342236B1/no
Priority to CN2007800424399A priority patent/CN101535326B/zh
Priority to UY30709A priority patent/UY30709A1/es
Priority to PE2007001553A priority patent/PE20081493A1/es
Priority to ARP070105027A priority patent/AR063786A1/es
Priority to TW096142599A priority patent/TWI414530B/zh
Priority to CL200703262A priority patent/CL2007003262A1/es
Publication of DE102006053635A1 publication Critical patent/DE102006053635A1/de
Priority to SV2009003216A priority patent/SV2009003216A/es
Priority to CR10733A priority patent/CR10733A/es
Priority to NI200900076A priority patent/NI200900076A/es
Priority to CO09045559A priority patent/CO6190534A2/es
Priority to TNP2009000180A priority patent/TN2009000180A1/fr
Priority to IL198718A priority patent/IL198718A/en
Priority to MA31864A priority patent/MA30883B1/fr
Priority to EC2009009327A priority patent/ECSP099327A/es
Priority to GT200900125A priority patent/GT200900125A/es
Priority to US12/465,911 priority patent/US7956085B2/en
Priority to CY20111100133T priority patent/CY1111166T1/el
Application granted granted Critical
Publication of DE102006053635B4 publication Critical patent/DE102006053635B4/de
Priority to ARP170101938A priority patent/AR109033A2/es
Priority to NO20180497A priority patent/NO344589B1/no
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/027—Keto-aldonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DE102006053635A 2006-11-14 2006-11-14 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Expired - Fee Related DE102006053635B4 (de)

Priority Applications (42)

Application Number Priority Date Filing Date Title
DE102006053635A DE102006053635B4 (de) 2006-11-14 2006-11-14 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CN2007800424399A CN101535326B (zh) 2006-11-14 2007-10-30 被苄基取代的1,4-苯并硫杂*-1,1-二氧化物衍生物、其制备方法、含有所述化合物的药物以及其用途
DK07819434.7T DK2084172T3 (da) 2006-11-14 2007-10-30 Nye 1,4-benzothiepin-1,1-dioxidderivater, som er substitueret med benzylrester, fremgangsmåde til deres fremstilling, lægemidler, der indeholder disse forbindelser, og deres anvendelse
CA2865332A CA2865332C (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
RU2009122470/04A RU2456282C2 (ru) 2006-11-14 2007-10-30 Новые бензилзамещенные производные 1,4-бензотиепин-1,1-диоксида
MX2009003958A MX2009003958A (es) 2006-11-14 2007-10-30 Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso.
JP2009536625A JP5301453B2 (ja) 2006-11-14 2007-10-30 ベンジル基によって置換された新規な１，４−ベンゾチエピン１，１−ジオキシド誘導体、その製造方法、その化合物を含む医薬及びその使用
ES07819434T ES2358371T3 (es) 2006-11-14 2007-10-30 Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, procedimiento para su preparación, medicamentos que contienen estos compuestos y su uso.
HK10102412.4A HK1137762B (en) 2006-11-14 2007-10-30 1, 4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
AU2007321496A AU2007321496B2 (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
KR1020097009914A KR101489168B1 (ko) 2006-11-14 2007-10-30 벤질 그룹으로 치환된 신규한 1,4-벤조티에핀-1,1-디옥사이드 유도체, 당해 화합물을 포함하는 약제의 제조방법 및 이의 용도
AT07819434T ATE492554T1 (de) 2006-11-14 2007-10-30 Neue mit benzylresten substituierte 1,4- benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
HR20110197T HRP20110197T1 (hr) 2006-11-14 2007-10-30 Novi benzilnim skupinama supstituirani derivati 1,4-benzotiepin-1,1-dioksida, postupak njihovog dobivanja, lijekovi koji ih sadrže i njihova upotreba
DE502007006055T DE502007006055D1 (de) 2006-11-14 2007-10-30 Neue mit benzylresten substituierte 1,4-benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
PCT/EP2007/009393 WO2008058628A1 (de) 2006-11-14 2007-10-30 Neue mit benzylresten substituierte 1,4-benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
NZ576762A NZ576762A (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof
CA2669230A CA2669230C (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
BRPI0718813A BRPI0718813B8 (pt) 2006-11-14 2007-10-30 compostos derivados de 1,1-dióxido de 1,4-benzotiepina, medicamento que os compreendem e seus usos
PT07819434T PT2084172E (pt) 2006-11-14 2007-10-30 Novos derivados de 1,1-dióxido de 1,4-benzotiepina substituídos com resíduos benzilo, processo para a sua preparação, produtos farmacêuticos contendo estes compostos e sua utilização
SI200730487T SI2084172T1 (sl) 2006-11-14 2007-10-30 Novi z benzilnimi ostanki substituirani 1,4-benzotiepin-1,1-dioksidni derivati, postopek za njihovo izdelavo, te spojine vsebujoča zdravila in njihova uporaba
MYPI20091688A MY148429A (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
NO20091893A NO342236B1 (no) 2006-11-14 2007-10-30 Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmåter for fremstilling av medikamenter inneholdende disse forbindelser, samt deres anvendelse
PL07819434T PL2084172T3 (pl) 2006-11-14 2007-10-30 Nowe pochodne 1,1-ditlenku 1,4-benzotiepiny podstawione resztami benzylowymi, sposób ich wytwarzania, środki lecznicze zawierające te związki i ich zastosowanie
EP07819434A EP2084172B1 (de) 2006-11-14 2007-10-30 Neue mit benzylresten substituierte 1,4-benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
TW096142599A TWI414530B (zh) 2006-11-14 2007-11-12 新穎之經苄基基團取代之１，４-苯并硫呯１，１-二氧化物衍生物，製備彼等之方法，含此類化合物之醫藥品，及其用途
UY30709A UY30709A1 (es) 2006-11-14 2007-11-12 Nuevos derivados de 1,4-benzotiepina-1, 1-dioxido sustituidos con radicales bencilo, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
PE2007001553A PE20081493A1 (es) 2006-11-14 2007-11-12 Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso
ARP070105027A AR063786A1 (es) 2006-11-14 2007-11-12 Derivados de 1,4 -benzotiepina-1,1 dioxido sustituidos con radicales bencilo, productos farmaceuticos que comprenden estos compuestos y su uso
CL200703262A CL2007003262A1 (es) 2006-11-14 2007-11-13 Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
SV2009003216A SV2009003216A (es) 2006-11-14 2009-04-03 Nuevos derivados de 1, 4-benzotiepina 1, 1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos, y su uso
CR10733A CR10733A (es) 2006-11-14 2009-04-20 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
NI200900076A NI200900076A (es) 2006-11-14 2009-05-04 Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso.
CO09045559A CO6190534A2 (es) 2006-11-14 2009-05-06 Nuevos derivados de 1,4 benzotiepina-1, 1-dioxido sustituido con radicales bencilo metodo para su preparacion productos farmaceuticos que comprenden estos compuestos y su uso
TNP2009000180A TN2009000180A1 (en) 2006-11-14 2009-05-08 NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
MA31864A MA30883B1 (fr) 2006-11-14 2009-05-12 Nouveaux derives de 1,1 - dioxyde de 1.4 - benzothiepine substitues par des radicaux benzyle, leur procede de preparation, les produits pharmaceutiques comprenant ces composes et leur utilisation
IL198718A IL198718A (en) 2006-11-14 2009-05-12 Derivatives of 1,4-benzothiazepine-1,1-dioxide converted into benzyl groups, a method for producing drugs and their use
EC2009009327A ECSP099327A (es) 2006-11-14 2009-05-13 Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso
GT200900125A GT200900125A (es) 2006-11-14 2009-05-13 Nuevos derivados de 1,4-benzotiepina-1, 1-dioxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso.
US12/465,911 US7956085B2 (en) 2006-11-14 2009-05-14 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof
CY20111100133T CY1111166T1 (el) 2006-11-14 2011-02-04 Νεα παραγωγα 1,4-βενζοθειεπινο-1,1-διοξειδιου υποκατεστημενα με ριζες βενζυλιου, μεθοδοι διεργασιων για την παρασκευη τους, φαρμακα που περιεχουν αυτες τις ενωσεις και η χρηση τους
ARP170101938A AR109033A2 (es) 2006-11-14 2017-07-12 Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso
NO20180497A NO344589B1 (no) 2006-11-14 2018-04-11 Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, farmasøytiske preparater inneholdende slike forbindelser, samt deres anvendelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006053635A DE102006053635B4 (de) 2006-11-14 2006-11-14 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Publications (2)

Publication Number Publication Date
DE102006053635A1 DE102006053635A1 (de) 2008-05-15
DE102006053635B4 true DE102006053635B4 (de) 2011-06-30

Family

ID=39092812

Family Applications (2)

Application Number Title Priority Date Filing Date
DE102006053635A Expired - Fee Related DE102006053635B4 (de) 2006-11-14 2006-11-14 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE502007006055T Active DE502007006055D1 (de) 2006-11-14 2007-10-30 Neue mit benzylresten substituierte 1,4-benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502007006055T Active DE502007006055D1 (de) 2006-11-14 2007-10-30 Neue mit benzylresten substituierte 1,4-benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Country Status (37)

Country Link
US (1) US7956085B2 (https=)
EP (1) EP2084172B1 (https=)
JP (1) JP5301453B2 (https=)
KR (1) KR101489168B1 (https=)
CN (1) CN101535326B (https=)
AR (2) AR063786A1 (https=)
AT (1) ATE492554T1 (https=)
AU (1) AU2007321496B2 (https=)
BR (1) BRPI0718813B8 (https=)
CA (2) CA2865332C (https=)
CL (1) CL2007003262A1 (https=)
CO (1) CO6190534A2 (https=)
CR (1) CR10733A (https=)
CY (1) CY1111166T1 (https=)
DE (2) DE102006053635B4 (https=)
DK (1) DK2084172T3 (https=)
EC (1) ECSP099327A (https=)
ES (1) ES2358371T3 (https=)
GT (1) GT200900125A (https=)
HR (1) HRP20110197T1 (https=)
IL (1) IL198718A (https=)
MA (1) MA30883B1 (https=)
MX (1) MX2009003958A (https=)
MY (1) MY148429A (https=)
NI (1) NI200900076A (https=)
NO (2) NO342236B1 (https=)
NZ (1) NZ576762A (https=)
PE (1) PE20081493A1 (https=)
PL (1) PL2084172T3 (https=)
PT (1) PT2084172E (https=)
RU (1) RU2456282C2 (https=)
SI (1) SI2084172T1 (https=)
SV (1) SV2009003216A (https=)
TN (1) TN2009000180A1 (https=)
TW (1) TWI414530B (https=)
UY (1) UY30709A1 (https=)
WO (1) WO2008058628A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK2282991T3 (en) * 2008-05-02 2018-05-07 Sanofi Aventis Deutschland METHOD OF PREPARING 1,4-BENZOTHIEPINE-1,1-DIOXIDE DERIVATIVES
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2012328526B2 (en) * 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20130108573A1 (en) * 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
ES2874669T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
CN108601739B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 考来烯胺丸剂及其制备方法
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
EP3664782B1 (en) 2017-08-09 2025-01-29 Albireo AB Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
PL3810581T3 (pl) 2018-06-20 2025-04-28 Albireo Ab Modyfikacje kryształu odewiksibatu
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
CN118852054A (zh) 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
IL293379B2 (en) 2019-12-04 2026-04-01 Albireo Ab Benzothia(dia)azepine compounds and their use as bile acid modulators
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4069247B1 (en) 2019-12-04 2025-03-26 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
EP4511038A1 (en) 2022-04-22 2025-02-26 Albireo AB Subcutaneous administration of an asbt inhibitor
KR20250022025A (ko) 2022-06-09 2025-02-14 알비레오 에이비 간염 치료
AU2023390975A1 (en) 2022-12-09 2025-06-05 Albireo Ab Asbt inhibitors in the treatment of renal diseases
CN121175041A (zh) * 2023-05-19 2025-12-19 米鲁姆制药公司 包含2,3,4,5-四氢-苯并噻庚环-1,1-二氧化物衍生物的药物组合物和其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018024A1 (de) * 2001-08-22 2003-03-06 Aventis Pharma Deutschland Gmbh Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
BR0213501A (pt) 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018024A1 (de) * 2001-08-22 2003-03-06 Aventis Pharma Deutschland Gmbh Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung

Also Published As

Publication number Publication date
SV2009003216A (es) 2010-05-26
ATE492554T1 (de) 2011-01-15
SI2084172T1 (sl) 2011-03-31
US20100035961A1 (en) 2010-02-11
AU2007321496A1 (en) 2008-05-22
NO20091893L (no) 2009-07-09
CY1111166T1 (el) 2015-06-11
MA30883B1 (fr) 2009-11-02
UY30709A1 (es) 2008-07-03
WO2008058628A1 (de) 2008-05-22
NO20180497A1 (no) 2009-07-09
NI200900076A (es) 2010-01-29
TW200837072A (en) 2008-09-16
KR101489168B1 (ko) 2015-02-03
CN101535326B (zh) 2012-10-31
AR063786A1 (es) 2009-02-18
RU2009122470A (ru) 2010-12-20
DK2084172T3 (da) 2011-04-04
IL198718A0 (en) 2010-02-17
JP2010509379A (ja) 2010-03-25
EP2084172B1 (de) 2010-12-22
IL198718A (en) 2012-12-31
GT200900125A (es) 2011-06-23
CO6190534A2 (es) 2010-08-19
NO344589B1 (no) 2020-02-03
MX2009003958A (es) 2009-04-27
HK1137762A1 (en) 2010-08-06
MY148429A (en) 2013-04-30
BRPI0718813B1 (pt) 2020-12-08
CA2669230C (en) 2015-01-13
CA2669230A1 (en) 2008-05-22
DE102006053635A1 (de) 2008-05-15
CL2007003262A1 (es) 2008-05-30
EP2084172A1 (de) 2009-08-05
PE20081493A1 (es) 2008-11-24
JP5301453B2 (ja) 2013-09-25
HRP20110197T1 (hr) 2011-04-30
ES2358371T3 (es) 2011-05-10
CA2865332A1 (en) 2008-05-22
BRPI0718813B8 (pt) 2021-05-25
CN101535326A (zh) 2009-09-16
DE502007006055D1 (de) 2011-02-03
ECSP099327A (es) 2009-06-30
AU2007321496B2 (en) 2012-07-26
TWI414530B (zh) 2013-11-11
NZ576762A (en) 2010-11-26
US7956085B2 (en) 2011-06-07
NO342236B1 (no) 2018-04-23
BRPI0718813A2 (pt) 2013-12-03
RU2456282C2 (ru) 2012-07-20
CR10733A (es) 2009-05-25
CA2865332C (en) 2016-03-29
AR109033A2 (es) 2018-10-24
TN2009000180A1 (en) 2010-10-18
KR20090082396A (ko) 2009-07-30
PL2084172T3 (pl) 2011-06-30
PT2084172E (pt) 2011-02-10

Similar Documents

Publication Publication Date Title
DE102006053635B4 (de) Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053637B4 (de) Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2083832B1 (de) Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2084143B1 (de) Neue mit cyclohexylresten substituierte1,4-benzothiepin-1,1 -dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2203416B1 (de) (carboxylalkylen-phenyl)-phenyl-oxalamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP2203415B1 (de) (cyclopropyl-phenyl)-phenyl-oxalamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE102006021878A1 (de) Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2203448B1 (de) Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2008052658A1 (de) Neues mit piperazin-1-sulfonsäure substituiertes diphenylazetidinon mit verbesserten pharmakologischen eigenschaften
DE102007063671A1 (de) Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2683702B1 (de) Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102007005045B4 (de) Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
R018 Grant decision by examination section/examining division
R020 Patent grant now final

Effective date: 20111001

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20130601